Novartis Pharma Ag
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$4.3Mgeneral payments (2019-2025)
$2.2Mresearch payments (2019-2025)
555clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Leqvio $118K associated (2023-2025)
- Cosentyx $111K associated (2023-2025)
- Kesimpta $70K associated (2023-2025)
- Scemblix $67K associated (2023-2025)
- Kisqali $61K associated (2023-2025)
- Zolgensma $50K associated (2023-2025)
- Entresto $43K associated (2023-2025)
- Rhapsido $40K associated (2023-2025)
- Piqray $40K associated (2023-2025)
- Ilaris $35K associated (2023-2025)
- Kymriah $31K associated (2023-2025)
- Jakafi $31K associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Arshad Khanani | Reno, NV | Ophthalmology | $148,315.53 |
| Justis Ehlers | Cleveland, OH | Ophthalmology | $111,725.00 |
| Scott Solomon | Boston, MA | Cardiovascular Disease | $110,067.57 |
| Charles Wykoff | Bellaire, TX | Ophthalmology | $102,246.09 |
| Atulya Deodhar | Portland, OR | Rheumatology | $96,842.18 |
| Jeffrey Heier | Boston, MA | Retina Specialist | $87,840.49 |
| Srinivas Sadda | Pasadena, CA | Ophthalmology | $77,348.02 |
| Peter Kaiser | Cleveland, OH | Ophthalmology | $76,476.00 |
| Philip Mease | Seattle, WA | Rheumatology | $75,622.49 |
| Stephen Russell | Iowa City, IA | Ophthalmology | $71,895.38 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.